Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bismuth or Metronidazole in PPI-Amoxicillin Therapy for H. pylori
NCT05014685Phase 4Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, randomised trial of bismuth subcitrate and metronidazole in Helicobacter pylori infection (4 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Eradication rate of Helicobacter pylori. Status: unknown.
02
Drugs
bismuth subcitratemetronidazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05014685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05014685.